Abstract 1165P
Background
Melanoma in-transit metastasis (ITM) occurs in up to 20% of patients with cutaneous melanoma. The 10-year melanoma-specific survival for patients with ITM varies from 75% to 43%. Anti-PD-1-based immunotherapy is used when patients develop unresectable stage III disease or distant metastasis (stage IV). The tumour microenvironment (TME) of ITM melanoma remains poorly understood, where distinct cellular and spatial features can influence patients’ outcome to therapy. This study aims to characterise the spatial TME in ITM melanoma patients.
Methods
We performed 40-plex PhenoCycler imaging on FFPE whole-tissue sections and CITE-Seq using tumour dissociates from 20 ITM patients treated with immunotherapy, 10 biopsied at baseline and 10 biopsied at the time of progression. Using bioinformatic analysis including spatial neighbourhood characterisation and receptor-ligand analyses, we investigated the TME features in ITM melanoma.
Results
Spatial neighbourhood analysis identified tertiary lymphoid structures (TLSs) consisting of B cells, CD8+ T cells and dendritic cells, and these immune cells are interfacing HLA-Ahigh melanoma at the tumour margin. An enrichment for TLSs in pre-treatment ITM was associated with good immunotherapy outcome. Distinct subtypes of macrophages were stratified by phenotypic marker expression and spatial location, and intratumoural enrichment of M1-like macrophages (CD68+HLA-DR+CD107a+CD163-) was associated with immunotherapy response. Intra-tumoural melanoma heterogeneity was demonstrated in ITMs from patients with primary resistance to treatment and at progression. The resistant TME subtypes displayed a multitude of immune evasive phenotypes, including the upregulation of immune checkpoint receptors (LAG3, VISTA, IDO1), high proliferation, collagen deposition, and low immune recruitment. Single cell sequencing analysis demonstrates cellular programs correlated with response and resistance features in ITM patients.
Conclusions
Taken together, these findings provide insights into the spatial TME interactions associated with immunotherapy response, facilitating the development of biomarkers and therapeutic targets.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Melanoma Institute Australia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1110P - A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma
Presenter: Tu Hu
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13